FDA Approves New Breast Cancer Treatment Drug

1. FDA Approves New Breast
Cancer Treatment Drug
By: Eloah Rocha

2. FDA Approves New Breast Cancer Treatment Drug
The recipient of a bachelor's degree in child psychology from the University of Colorado Boulder,
Eloah Rocha has served as a youth counselor at Children's Hospital Los Angeles since 2004. In
addition to her work, Eloah Rocha is a supporter of causes that benefit breast cancer patients.

3. FDA Approves New Breast Cancer Treatment Drug
A potentially impactful breakthrough was made in regard to breast cancer on March 11, 2019, as the
US Food and Drug Administration (FDA) approved Roche's Tecentriq for the treatment of advanced
triple-negative breast cancer, which accounts for roughly 15 percent of all breast cancer cases.
Tecentriq, which is to be used in combination with chemotherapy, is the first FDA-approved
immunotherapy drug used to treat breast cancer.

4. FDA Approves New Breast Cancer Treatment Drug
The approval comes after a study of 900 women found that subjects who took Tecentriq and
underwent chemotherapy continued an average of two months longer without experiencing worsening
conditions. Tecentriq, which costs $13,400 per month, improves the immune system's ability to detect
and kill cancerous cells.

5. FDA Approves New Breast Cancer Treatment Drug
While Tecentriq is an expensive drug with only modest results in stalling the progression of breast
cancer, it's a first-of-its-kind breakthrough that represents a significant step forward in
understanding and treating advanced triple-negative breast cancer.